Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Neil D GrossDavid Michael MillerNikhil I KhushalaniVasu DiviEmily S RuizEvan J LipsonFriedegund MeierYungpo B SuPaul L SwiecickiJennifer AtlasJessica L GeigerAxel HauschildJennifer H ChoeBrett G M HughesDirk SchadendorfVishal A PatelJade HomsiJanis M TaubeAnnette M LimRenata FerrarottoHoward L KaufmanFrank SeebachIsrael LowySuk-Young YooMelissa MathiasKeilah FenechHyunsil HanMatthew G FuryDanny RischinPublished in: The New England journal of medicine (2022)
Neoadjuvant therapy with cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable cutaneous squamous-cell carcinoma. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov number, NCT04154943.).